Drug development

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 20, 2023
Michael G. DeGroote School of Medicine, Drug development, Therapy, Research, CCCC, Bladder cancer, Genentech, Chemistry, National Cancer Institute, Queen Elizabeth, McMaster University, Patient, Queen Elizabeth II Health Sciences Centre, Astellas Pharma, Sanofi, FDA, Breast cancer, Disease, Pharmaceutical industry, Dalhousie

WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Leonard (Len) Reyno, M.D., as chief medical officer, effective July 10, 2023. Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.

Key Points: 
  • Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials.
  • At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.
  • “We look forward to leveraging Len’s track record of advancing novel oncology therapeutics to patients, deep strategic and operational experience in clinical development and organizational leadership capabilities,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
  • Prior to Pionyr, he was executive vice president and chief medical officer at ORIC Pharmaceuticals, leading their first product candidate into human trials.

MRCT Center and Medable Launch First, Comprehensive IRB/EC Review Toolkit for Decentralized Clinical Trials

Retrieved on: 
Tuesday, June 20, 2023
Data Management, Biotechnology, Technology, FDA, Health, Pharmaceutical, Medical Devices, Research, Software, Science, Clinical Trials, Faculty, Tufts Center for the Study of Drug Development, Public, ECS, Clinical trial, Data collection, Innovation, EST, Multimedia, Committee, DCT, DCTS, Harvard University, Bangladesh Technical Education Board, Ethics, Trial of the century, Harvard Medical School, Certified IRB Professional, Patient, IRB, OHRP, Office for Human Research Protections, Annual general meeting, Drug development, Hospital, Institutional review board, DIA, EC, Food, Medical device, Medicine

Medable Inc. , the leading technology provider for patient-centric clinical trials, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) announce a comprehensive toolkit for Institutional Review Boards (IRBs)/Ethics Committees (ECs) to standardize decentralized clinical trial (DCT) ethics review.

Key Points: 
  • Medable Inc. , the leading technology provider for patient-centric clinical trials, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) announce a comprehensive toolkit for Institutional Review Boards (IRBs)/Ethics Committees (ECs) to standardize decentralized clinical trial (DCT) ethics review.
  • The first-of-its-kind toolkit provides a common framework, tools, and best practices for uniform ethical review and approval and provides a roadmap for the ethical conduct of DCTs.
  • View the full release here: https://www.businesswire.com/news/home/20230620838809/en/
    MRCT Center and Medable Launch Comprehensive IRB/EC Review Toolkit for DCTs (Graphic: Business Wire)
    “The new DCT IRB/EC Review Toolkit will ease ethics reviews of decentralized trials by establishing commonality and removing some of the guesswork that has made DCT reviews cumbersome,” said Dr. Barbara Bierer , Professor of Medicine at Harvard Medical School and Faculty Director of the MRCT Center.
  • Medable’s customers have achieved impressive results with decentralized and hybrid trials – including 200 percent faster enrollment and 50 percent cost reductions.

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, Technology, Professional Services, Health, Oncology, Health Technology, Research, Data Analytics, Software, Artificial Intelligence, Science, MSD, CRISPR, Drug development, Genomics, Biogen, Intelligence, Bristol Myers Squibb, Genome, Biomarker, Princeton University, Harvard Medical School, Milind, Bayer, GPC Biotech, Genome Therapeutics Corporation, Novartis, Patient, Commercial Affairs Department, MMV, Machine learning, Drug combination, Corporation, Drug discovery, Sanofi, Faculty, Entrepreneurship, Merck, AI, Merck & Co., Bavarian Nordic, Massachusetts General Hospital, Therapy, Medical device, Pharmaceutical industry, Management, Turbine

This investment brings the company’s oversubscribed Series A round to €25.5 million and adds further U.S.-based investors to the company’s financing syndicate.

Key Points: 
  • This investment brings the company’s oversubscribed Series A round to €25.5 million and adds further U.S.-based investors to the company’s financing syndicate.
  • Alongside the funding, Turbine announced the appointments of four independent directors to its board.
  • They also have the capacity to perform assays that would be impractical to conduct at scale and with high throughput.
  • Dr. Wegner believes Turbine’s pairing of AI with advanced biotechnology gives it potential to powerfully impact the future of healthcare.

Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders

Retrieved on: 
Tuesday, June 20, 2023
Medical Devices, Health, Neurology, Health Technology, Pharmaceutical, Biotechnology, Drug development, Adrenoleukodystrophy, Professor, ALD, ESPCI, Hospital, Medical physics, Ageing, DSM-IV codes, Software, Multimedia, Brain, Engineer, Biomarker, Doctor of Philosophy, Harvard University, Intensivist, MRI, Alzheimer's disease, Parkinson's disease, Magnetic resonance imaging, Neuroscience, Patient, Myenteric plexus, Physician, Coma, Observation, White matter, Diagnosis, ALS, Pharmaceutical industry, Medical imaging, Software as a service, Neuroradiology, Atlantic Ocean

To explore this new continent of the brain, BrainTale is developing a measurement solution that improves diagnosis, monitoring and prediction with a non-invasive, pain-free, efficient and clinically validated approach.

Key Points: 
  • To explore this new continent of the brain, BrainTale is developing a measurement solution that improves diagnosis, monitoring and prediction with a non-invasive, pain-free, efficient and clinically validated approach.
  • "This fundraising is a decisive step for BrainTale, and enables us to look forward with ambition to our next development milestones.
  • BrainTale improves the practice of healthcare professionals and the quality of care by improving the prediction of neurological diseases such as Alzheimer's and Parkinson's diseases.
  • This round of financing will enable BrainTale to enter a new phase in its development," states Sébastien Couvet, head of the MACSF Group's e-health portfolio.

Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment

Retrieved on: 
Tuesday, June 20, 2023
Magnet, IIT, Thermosome, Drug development, Sarcoma, Neoplasm, German, Hyperthermia, Lung cancer, BMBF, STS, Federal Ministry of Health (Germany), Teaching hospital, Liver cancer, Turku University Hospital, EUR, MRI, Patient, Doxorubicin, Philips, Education, Safety, Medical imaging, Research

Consortium aims to improve clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas

Key Points: 
  • Consortium aims to improve clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas
    Munich, Germany – June 20, 2023 – Thermosome, a drug development company specializing in targeted tumor therapies, today announced its participation in the IMAGIO consortium set out to develop innovations in interventional oncology focused on lung cancer, liver cancer and soft tissue sarcomas (STS).
  • "We are delighted to be part of the IMAGIO consortium, and we look forward to expanding our collaboration with the University Hospital of Cologne," said Dr. Pascal Schweizer, co-founder and CEO/CFO of Thermosome.
  • IMAGIO will build on this project and also consider the results of our ongoing Phase I trial of THE001, which was initiated earlier this year."
  • I strongly believe that this project will nicely integrate these components, paving the way for broader clinical use of this approach.”

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program

Retrieved on: 
Tuesday, June 20, 2023
Protein splicing, University, GSK plc, GSK, Drug development, Doctor of Philosophy, HIV, Stargardt disease, Education minister, Stargardt, Immunotherapy, St. Andrews University (North Carolina), AAV, CDO, Biology, Translational medicine, DSM-IV codes, UCSF, IND, Gladstone Institutes, Gene, Bangladesh Technical Education Board, Medical device, Pharmaceutical industry, Vaccine, Science, Microbiology

Dr. Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry.

Key Points: 
  • Dr. Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry.
  • He joins SpliceBio from Innoskel, where he served as Chief Scientific Officer.
  • David will focus on advancing the company's lead AAV gene therapy program for Stargardt disease towards clinical development and expanding the company's Protein Splicing platform and pipeline to other genes that exceed the packaging capacity of AAV vectors."
  • David Favre, CDO of SpliceBio, commented: "SpliceBio has built an impressive gene therapy platform that addresses one of the most fundamental challenges facing the gene therapy field today: the limited packaging capacity of AAV vectors.

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program

Retrieved on: 
Tuesday, June 20, 2023
Protein splicing, University, GSK plc, GSK, Drug development, Doctor of Philosophy, HIV, Stargardt disease, Education minister, Stargardt, Immunotherapy, St. Andrews University (North Carolina), AAV, CDO, Biology, Translational medicine, DSM-IV codes, UCSF, IND, Gladstone Institutes, Gene, Bangladesh Technical Education Board, Medical device, Pharmaceutical industry, Vaccine, Science, Microbiology

Dr. Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry.

Key Points: 
  • Dr. Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry.
  • He joins SpliceBio from Innoskel, where he served as Chief Scientific Officer.
  • David will focus on advancing the company's lead AAV gene therapy program for Stargardt disease towards clinical development and expanding the company's Protein Splicing platform and pipeline to other genes that exceed the packaging capacity of AAV vectors."
  • David Favre, CDO of SpliceBio, commented: "SpliceBio has built an impressive gene therapy platform that addresses one of the most fundamental challenges facing the gene therapy field today: the limited packaging capacity of AAV vectors.

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer

Retrieved on: 
Tuesday, June 20, 2023
GSK, Drug development, Research, CMO, Doctor of Philosophy, AstraZeneca, Eisai, MD, Patient, Cancer, Duality, ADC, Spacecraft, Aarhus University, Health, Lone, Pharmaceutical industry, Nursing, Fine chemical

Dr. Ottesen is a highly accomplished drug developer with extensive global clinical development experience across oncology and immune-oncology with a track record of more than 20 years in both early- and late-phase clinical development.

Key Points: 
  • Dr. Ottesen is a highly accomplished drug developer with extensive global clinical development experience across oncology and immune-oncology with a track record of more than 20 years in both early- and late-phase clinical development.
  • Dr. Ottesen held roles of increasing seniority in Global Oncology Development at GSK, Eisai and most recently at AstraZeneca, where
    she was Global Clinical Head in Late-Stage Clinical Development.
  • She joins Adcendo from Circio, formerly known as Targovax, where she was Chief Medical Officer and previously Chief Development Officer.
  • Lone Ottesen, incoming Chief Medical Officer at Adcendo, said "ADCs are at the forefront of a paradigm shift in cancer chemotherapy, and I am excited to join Adcendo to shape its IND-enabling activities and clinical plans.

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer

Retrieved on: 
Tuesday, June 20, 2023
GSK, Drug development, Research, CMO, Doctor of Philosophy, AstraZeneca, Eisai, MD, Patient, Cancer, Duality, ADC, Spacecraft, Aarhus University, Health, Lone, Pharmaceutical industry, Nursing, Fine chemical

Dr. Ottesen is a highly accomplished drug developer with extensive global clinical development experience across oncology and immune-oncology with a track record of more than 20 years in both early- and late-phase clinical development.

Key Points: 
  • Dr. Ottesen is a highly accomplished drug developer with extensive global clinical development experience across oncology and immune-oncology with a track record of more than 20 years in both early- and late-phase clinical development.
  • Dr. Ottesen held roles of increasing seniority in Global Oncology Development at GSK, Eisai and most recently at AstraZeneca, where
    she was Global Clinical Head in Late-Stage Clinical Development.
  • She joins Adcendo from Circio, formerly known as Targovax, where she was Chief Medical Officer and previously Chief Development Officer.
  • Lone Ottesen, incoming Chief Medical Officer at Adcendo, said "ADCs are at the forefront of a paradigm shift in cancer chemotherapy, and I am excited to join Adcendo to shape its IND-enabling activities and clinical plans.

Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 19, 2023
Health, Oncology, Clinical Trials, Pharmacy, Triple-negative breast cancer, Monoclonal antibody, Patent, Drug development, TIL, Patent analysis, Cancer, Immunotherapy, Prognosis, Biomarker, Antibody, Dose, Gardening, Drug resistance, Incidence, TILS, Investment, Patient, Immune system, Potyvirus, Escape Room, Growth, Merck, Recurrence, Breast cancer, Disease, Bone marrow, Dietary supplement, Pharmaceutical industry, Vaccine, Price, Pembrolizumab

The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering.
  • The introduction of immunotherapy, particularly immune checkpoint inhibitors has transformed the treatment for breast cancer, with immunotherapy being effective even in aggressive forms of breast cancer such as triple-negative breast cancer.
  • It can be said that immune checkpoint inhibitors have been a vital factor that has resulted in the growing market of breast cancer immunotherapy.
  • Additionally, moving beyond immune checkpoint inhibitors, the market of breast cancer immunotherapy is also witnessing a rise in novel treatment approaches.